In the last trading session, 2.56 million Prime Medicine Inc (NASDAQ:PRME) shares changed hands as the company’s beta touched 1.59. With the company’s per share price at $1.59 changed hands at $0.33 or 26.19% during last session, the market valuation stood at $208.76M. PRME’s last price was a discount, traded about -420.13% off its 52-week high of $8.27. The share price had its 52-week low at $1.12, which suggests the last value was 29.56% up since then.
Analysts gave the Prime Medicine Inc (PRME) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.18. If we narrow down to specifics, the data shows that 0 out of 5 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 1 recommended PRME as a Hold, 4 felt it is a Buy and 0 rated the stock as Underweight.
Prime Medicine Inc (NASDAQ:PRME) trade information
Instantly PRME was in green as seen at the end of in last trading. With action 22.31%, the performance over the past five days has been green. The company’s shares are showing year-to-date downside of -45.55%, with the 5-day performance at 22.31% in the green. However, in the 30-day time frame, Prime Medicine Inc (NASDAQ:PRME) is 28.23% up.
The consensus price target for the stock as assigned by Wall Street analysts is 17, meaning bulls need an upside of 90.65% from its current market value. According to analyst projections, PRME’s forecast low is 12 with 23 as the target high. To hit the forecast high, the stock’s price needs a -1346.54% plunge from its current level, while the stock would need to soar -654.72% for it to hit the projected low.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -124.13%. The 2025 estimates are for Prime Medicine Inc earnings to increase by 19.67%, but the outlook for the next 5-year period is at 12.97% per year.
PRME Dividends
Prime Medicine Inc is expected to release its next quarterly earnings report in June.
ARK INVESTMENT MANAGEMENT LLC holds the second largest percentage of outstanding shares, with 5.1404% or 6.13 million shares worth $31.49 million as of 2024-06-30.
Among Mutual Funds, the top two as of Apr 30, 2025 were ARK ETF Trust-ARK Genomic Revolution ETF and VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund . With 2.34 shares estimated at $3.71 million under it, the former controlled 1.78% of total outstanding shares. On the other hand, VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund held about 1.60% of the shares, roughly 2.1 shares worth around $3.33 million.
